Securities Code: 300725 Securities Abbreviation: Yaoshi Technology Announcement No.: 2026-039
Nanjing Yaoshi Technology Co., Ltd.
Announcement on Adjusting the 2026 Annual Forecast for Routine Related-Party Transactions
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or significant omissions.
I. Basic Situation of Routine Related-Party Transactions
(I) Forecast of Routine Related-Party Transactions for 2026 Made Previously
On April 21, 2026, Nanjing Yaoshi Technology Co., Ltd. (hereinafter referred to as the "Company") held the 13th meeting of the Fourth Board of Directors, which reviewed and approved the "Proposal on Confirmation of 2025 Routine Related-Party Transactions and Forecast of 2026 Routine Related-Party Transaction Limits." Based on the actual situation of routine related-party transactions in 2025 and considering the needs of business development, it was forecasted that the related-party transactions that the Company might incur in 2026 would not exceed RMB 61.6 million. For details, please refer to the "Announcement on Confirmation of 2025 Routine Related-Party Transactions and Forecast of 2026 Routine Related-Party Transaction Limits" (Announcement No. 2026-020) disclosed on the Juchao Information Network on April 22, 2026.
On July 3, 2026, the Company held the 15th meeting of the Fourth Board of Directors, which reviewed and approved the "Proposal on Adjusting the 2026 Routine Related-Party Transaction Forecast." Due to the needs of the Company's business development and operational activities, in addition to the previously reviewed 2026 routine related-party transaction forecast, the Company's sales of goods and provision of services to Nanjing Jingjie Biotechnology Co., Ltd. and its related companies are expected to increase by RMB 41 million from the original RMB 21 million to RMB 62 million. For details, please refer to the "Announcement on Adjusting the 2026 Routine Related-Party Transaction Forecast" (Announcement No. 2026-033) disclosed on the Juchao Information Network on July 3, 2026.
(II) Forecast of Increased Routine Related-Party Transactions This Time
On August 9, 2026, the Company held the 16th meeting of the Fourth Board of Directors, which reviewed and approved the "Proposal on Adjusting the 2026 Routine Related-Party Transaction Forecast." Due to the needs of the Company's business development and operational activities, in addition to the previously reviewed 2026 routine related-party transaction forecast, the Company's sales of goods and provision of services to RETEX PHARMACEUTICALS, INC. and its related companies are expected to increase by RMB 10 million from the original RMB 25 million to RMB 35 million. The Company's sales of goods and provision of services to Nanjing KeluoSi Biotechnology Co., Ltd. are expected to increase by RMB 600 million from the original RMB 20 million to RMB 620 million.